A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer.

摘要: The purpose of this study was to assess the response rate and toxicity paclitaxel, carboplatin, bevacizumab (PCB) primary induction therapy for treatment advanced-stage ovarian carcinoma. Twenty patients were treated with paclitaxel (175 mg/m2), carboplatin (AUC 5 IV), (15 mg/kg) body weight; q21 days six cycles. Bevacizumab administered at cycles two through six. Patients received 116 PCB chemotherapy (median = 6, range 2–6) evaluable assessment. Grade 3 4 neutropenia developed in 23.3% 25% cycles, no incidence grades 3/4 thrombocytopenia or anemia. Prior cycle six, one patient removed from due grade neuropathy another excluded clinical deterioration. There gastrointestinal perforations, only demonstrated hypertension (HTN). No HTN observed. Eighteen evaluated following therapy. Six a complete (30%) ten exhibited partial (50%), resulting total 80%. One stable disease (5%), progression (5%). lack bowel perforations wound complications should mitigate some concerns regarding these side effects. This suggests that first-line can be safely previously untreated carcinoma patients. favorable results reasonable warrant additional larger population.